Cite
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
MLA
Schmitz, Alexander, et al. “Longitudinal Minimal Residual Disease Assessment in Multiple Myeloma Patients in Complete Remission - Results from the NMSG Flow-MRD Substudy within the EMN02/HO95 MM Trial.” BMC Cancer, vol. 22, no. 1, Feb. 2022, p. 147. EBSCOhost, https://doi.org/10.1186/s12885-022-09184-1.
APA
Schmitz, A., Brøndum, R. F., Johnsen, H. E., Mellqvist, U.-H., Waage, A., Gimsing, P., Op Bruinink, D. H., van der Velden, V., van der Holt, B., Hansson, M., Andersen, N. F., Frølund, U. C., Helleberg, C., Schjesvold, F. H., Ahlberg, L., Gulbrandsen, N., Andreasson, B., Lauri, B., Haukas, E., … Dybkær, K. (2022). Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 22(1), 147. https://doi.org/10.1186/s12885-022-09184-1
Chicago
Schmitz, Alexander, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste Op Bruinink, et al. 2022. “Longitudinal Minimal Residual Disease Assessment in Multiple Myeloma Patients in Complete Remission - Results from the NMSG Flow-MRD Substudy within the EMN02/HO95 MM Trial.” BMC Cancer 22 (1): 147. doi:10.1186/s12885-022-09184-1.